Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master Protocol for Next-Gen NY-ESO-1/LAGE-1a TCR T-cells in Advanced Tumors
NCT04526509Phase 1Terminated
- Sponsor
- Adaptimmune Therapeutics
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 6
01
Overview
Phase 1, open-label trial of NY-ESO-1/LAGE-1a TCR-engineered T cells, GSK3845097 and GSK4427296 in non-small cell lung cancer (NSCLC), synovial sarcoma (SS) and myxoid round cell liposarcoma (MRCLPS) (4 arms), sponsored by Adaptimmune Therapeutics. Primary endpoint: Number of Participants Enrolled Across Sub Studies. Started Dec 2020; status: terminated.
02
Drugs
NY-ESO-1/LAGE-1a TCR-engineered T cellsGSK3845097GSK4427296
03
Conditions
non-small cell lung cancer (NSCLC)synovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)
Beyond the preview
Go deeper on NCT04526509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526509.